HARVARD BIOSCIENCE INC — Director's Dealing 2013

Nov 5, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2013-11-01

Reporting Person: LUSCINSKI SUSAN M (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-11-01	Common Stock	J	24201	—	Acquired	469720	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-11-01	Stock option (right to buy)	$5.73	J	35757	Acquired	2014-03-25	Common Stock, par value $0.01 per share (35757)	Direct
2013-11-01	Stock option (right to buy)	$2.14	J	11996	Acquired	2015-05-25	Common Stock, par value $0.01 per share (11996)	Direct
2013-11-01	Stock option (right to buy)	$3.07	J	19799	Acquired	2016-08-09	Common Stock, par value $0.01 per share (19799)	Direct
2013-11-01	Stock option (right to buy)	$3.99	J	31723	Acquired	2017-05-01	Common Stock, par value $0.01 per share (31723)	Direct
2013-11-01	Stock option (right to buy)	$2.28	J	48543	Acquired	2019-05-21	Common Stock, par value $0.01 per share (48543)	Direct
2013-11-01	Stock option (right to buy)	$4.04	J	11888	Acquired	2021-06-02	Common Stock, par value $0.01 per share (11888)	Direct
2013-11-01	Stock option (right to buy)	$2.56	J	25098	Acquired	2022-06-01	Common Stock, par value $0.01 per share (25098)	Direct
2013-11-01	Stock option (right to buy)	$3.64	J	11806	Acquired	2023-05-31	Common Stock, par value $0.01 per share (11806)	Direct

Footnotes

F1: These additional options and restricted stock units were acquired by the Reporting Person in connection with the adjustment to the existing options and restricted stock units held by the Reporting Person and required in connection with the spin-off of Harvard Apparatus Regenerative Technology, Inc. by the Issuer. As part of such required adjustment relating to the spin-off, the exercise price of the options underlying these adjustment option grants was also reset to the exercise price of these adjustment grants to reflect the impact of the spin-off. The share amounts and exercise prices of the adjusted options and restricted stock units were set in a manner to ensure the intrinsic value held by the Reporting Person pertaining to the existing award was maintained immediately following the spin-off. In addition to these adjustments, to maintain such intrinsic value, equity awards issued by Harvard Apparatus Regenerative Technology, Inc. were also granted to the Reporting Person.

F2: Includes (a) an adjusted deferred stock award of 21,992 restricted stock units which shall vest on Jan 1, 2014; (b) an adjusted deferred stock award of 12,347 restricted stock units which vest in equal installments on Jan 1, 2014 and Jan 1, 2015; (c) an adjusted deferred stock award of 40,764 restricted stock units which vest in equal installments on Jan 1, 2014, Jan 1, 2015, and Jan 1, 2016; (d) an adjusted deferred stock award of 25,465 restricted stock units which vest in equal installments on Jan 1, 2014, Jan 1, 2015, Jan 1, 2016, and Jan 1, 2017; and (e) 369,152 shares of common stock held by the Reporting Person.

F3: The option shares vested in four equal installments on January 1, 2005, 2006, 2007 and 2008.

F4: The option shares vested in four equal installments on January 1, 2006, 2007, 2008 and 2009.

F5: The option shares vested in four equal installments on January 1, 2007, 2008, 2009 and 2010.

F6: The option shares vested in four equal installments on January 1, 2008, 2009, 2010 and 2011.

F7: The option shares vested in four equal installments on January 1, 2010, 2011, 2012 and 2013

F8: The unvested shares become exercisable in equal installments on January 1 of each of 2014 and 2015.

F9: The unvested shares become exercisable in equal installments on January 1 of each of 2014, 2015 and 2016.

F10: The unvested shares become exercisable in equal installments on January 1 of each of 2014, 2015, 2016 and 2017.